It is recommended in Finland to use PrEP medicine to prevent HIV. New national guidelines recommend PrEP for individuals who are at high risk of contracting HIV. These guidelines will be published early 2019.
The biggest challenge implementing PrEP to Finnish health care is that the generic medicine is not available, and the original product is not affordable. The patent issue is in judicial process at the moment.
PrEP has decreased the amount of new HIV infections in all countries that it is available. There is strong evidence available about effectiveness of PrEP among men who have sex with men.
Hivpoint takes part in the biggest yearly event for medical doctors – DOCTOR 2019. It will be held in Helsinki from 9th to 11th of January. The experts from Hivpoint will lead discussions about benefits and challenges of PrEP medication.
More info on PrEP and the current situation in Finland here